8. Subsequent Events	3 Months Ended
Mar. 31, 2013
Subsequent Events [Abstract]
8. Subsequent Events	Resolute Oncology Inc. has evaluated and is disclosing the following subsequent events through the date these financial statements: On April 12, 2013, we completed due diligence and finalized a license agreement with Reliance Life Sciences Limited, an Indian pharmaceutical company, for certain rights to their PEG-Filgrastim product. We acquired the exclusive right to develop and commercialize a biosimilar therapeutic protein product also referred to as Pegylated Granulocyte Colony-Stimulating Factor (Peg-G-CSF). The agreement includes exclusive rights to commercialize the product in North America (U.S.A., Mexico and Canada), and in key Western and Eastern European markets. In consideration for product license and related rights, we paid a total of $500,000 to date. Other milestone and royalties will be due to Reliance Life Sciences upon successful completion of certain clinical and commercial milestones. On April 12, 2013, we closed a private placement by issuing 100,000 shares of our common stock at a price of $0.50 per share, for gross proceeds of $50,000. We issued the securities to one (1) U.S. person (at that term as defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933. On May 8, 2013, we completed the acquisition of Resolute Oncology GmbH, a newly-formed, single product company, from Oncocorp GmbH, a private pharmaceutical company selling cancer products in Germany. We paid 250,000 Euros, issued 1,000,000 million shares and will provide another 250,000 Euros and other payments to the owner of Oncocorp. Certain key mangers of Oncocorp will transfer to Resolute Oncology GmbH to manage German operations and the launch of additional Oncocorp generic products in the future. The company will be a wholly owned subsidiary of our Irish subsidiary company, Resolute Oncology Limited. Resolute Oncology Inc., the reporting Company and parent Company of Resolute Oncology Limited, is in the process of determining when or if it can file financial statements for the single product transferred to Resolute Oncology GmbH. There are currently no such financial statements available. On May 9, 2013, we issued a Convertible Note for $350,000. The note included issuance of warrants and certain collateral, as well as, other terms and conditions. The Note was issued to one (1) U.S. person (at that term as defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933.

8. Subsequent Events

3 Months Ended

Mar. 31, 2013

Resolute Oncology Inc. has evaluated and is disclosing the following subsequent events through the date these financial statements:

On April 12, 2013, we completed due diligence and finalized a license agreement with Reliance Life Sciences Limited, an Indian pharmaceutical company, for certain rights to their PEG-Filgrastim product. We acquired the exclusive right to develop and commercialize a biosimilar therapeutic protein product also referred to as Pegylated Granulocyte Colony-Stimulating Factor (Peg-G-CSF). The agreement includes exclusive rights to commercialize the product in North America (U.S.A., Mexico and Canada), and in key Western and Eastern European markets. In consideration for product license and related rights, we paid a total of $500,000 to date. Other milestone and royalties will be due to Reliance Life Sciences upon successful completion of certain clinical and commercial milestones.

On April 12, 2013, we closed a private placement by issuing 100,000 shares of our common stock at a price of $0.50 per share, for gross proceeds of $50,000. We issued the securities to one (1) U.S. person (at that term as defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933.

On May 8, 2013, we completed the acquisition of Resolute Oncology GmbH, a newly-formed, single product company, from Oncocorp GmbH, a private pharmaceutical company selling cancer products in Germany. We paid 250,000 Euros, issued 1,000,000 million shares and will provide another 250,000 Euros and other payments to the owner of Oncocorp. Certain key mangers of Oncocorp will transfer to Resolute Oncology GmbH to manage German operations and the launch of additional Oncocorp generic products in the future. The company will be a wholly owned subsidiary of our Irish subsidiary company, Resolute Oncology Limited. Resolute Oncology Inc., the reporting Company and parent Company of Resolute Oncology Limited, is in the process of determining when or if it can file financial statements for the single product transferred to Resolute Oncology GmbH. There are currently no such financial statements available.

On May 9, 2013, we issued a Convertible Note for $350,000. The note included issuance of warrants and certain collateral, as well as, other terms and conditions. The Note was issued to one (1) U.S. person (at that term as defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933.

RESOLUTE ONCOLOGY INC 10-Q